miR-146b在恶性肿瘤中的研究进展

doi:10.3969/j.issn.1004-583X.2021.08.019

摘要/Abstract

摘要：

微小RNA(microRNA,miRNA)是一类常见的非编码RNA,一般不被翻译为蛋白质,其主要作用是对基因表达进行调控。miRNA种类众多,作用机制十分复杂,其中miR-146b是一类多功能的miRNA,研究发现其在恶性胶质瘤、甲状腺癌、肺癌、肝细胞癌、胰腺癌、结直肠癌等诸多恶性肿瘤中的表达水平常常发生变化。本文就miR-146b的结构、主要作用机制以及在上述恶性肿瘤中的研究进展做一综述。

中图分类号:

R730.4

陶嘉楠, 王学红, 张宏琳. miR-146b在恶性肿瘤中的研究进展[J]. 临床荟萃, 2021, 36(8): 765-768.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.08.019

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I8/765

参考文献 40

[1]	Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5):843-854. pmid: 8252621
[2]	Zhang F, Zhang Y, Lv X, et al. Evolution of an X-linked miRNA family predominantly expressed in mammalian male germ cells[J]. Mol Biol Evol, 2019(4):663-678.
[3]	Fernandez N, Cordiner RA, Young RS, et al. Genetic variation and RNA structure regulate microRNA biogenesis[J]. Nat Commun, 2017, 8(3):151-154. doi: 10.1038/s41467-017-00207-1 URL
[4]	Bengone-Abogourin JG, Chelkha N, Verdin E, et al. Sequence similarities between viroids and human microRNAs[J]. Intervirology, 2020, 62(5-6):1-8. doi: 10.1159/000499466 URL
[5]	Li P, Chen Y, Juma CA, et al. Differential inhibition of target gene expression by human microRNAs[J]. Cells, 2019, 8(8):791 doi: 10.3390/cells8080791 URL
[6]	Kouzarides T, Pandolfini L, Barbieri I, et al. Further evidence supporting N7-methylation of guanosine (m7G) in human microRNAs[J]. Mol Cell, 2020, 79(2):201-202. doi: S1097-2765(20)30343-9 pmid: 32679073
[7]	Do DN, Dudemaine PL, Fomenky B, et al. Integration of miRNA weighted gene co-expression network and miRNA-mRNA co-expression analyses reveals potential regulatory functions of miRNAs in calf rumen development[J]. Genomics, 2019, 3(4):849-859.
[8]	Chen Q, Zhao Z, Lan W, et al. Predicting miRNA-disease interaction based on recommend method[J]. Inf Discov Deliv, 2019, 48(1):35-40.
[9]	Osmak G, Kiselev I, Baulina N, et al. From miRNA target gene network to miRNA function: miR-375 might regulate apoptosis and actin dynamics in the heart muscle via rho-GTPases-dependent pathways[J]. Int J Mol Sci, 2020, 21(24):9670. doi: 10.3390/ijms21249670 URL
[10]	Dagmar P, Eva R, Lang I, et al. MiR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an in vitro sepsis model[J]. PLoS One, 2017, 12(6):179-185.
[11]	Zhao H, Su W, Kang Q, et al. Natural killer cells inhibit oxaliplatin-resistant colorectal cancer by repressing WBSCR22 via upregulating microRNA-146b-5p[J]. Am J Cancer Res, 2018, 8(5):824-834.
[12]	Chou KC, Liu RT, Kang HY. MicroRNA-146b: a novel biomarker and therapeutic target for human papillary thyroid cancer[J]. Int J Mol Sci, 2017, 18(3):636. doi: 10.3390/ijms18030636 URL
[13]	Katakowski M, Zheng X, Jiang F, et al. MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma[J]. Cancer Invest, 2010, 28(10):1024-1030. doi: 10.3109/07357907.2010.512596 pmid: 20874002
[14]	Cai J, Xu L, Cai Z, et al. MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor[J]. Mol Med Rep, 2015, 12(1):1549-1555. doi: 10.3892/mmr.2015.3461 URL
[15]	William P, Juliann C. Rational, biologically based treatment of EGFR -mutant non-small-cell lung cancer[J]. Nat Rev Cancer, 2010, 10(11):760-768. doi: 10.1038/nrc2947 pmid: 20966921
[16]	Liu Y, Tsai MF, Wu SG, et al. MiR-146b-5p enhances the sensitivity of NSCLC to EGFR tyrosine kinase inhibitors by regulating the IRAK1/NF-κB pathway[J]. Mol Ther Nucleic Acids, 2020, 22:471-483. doi: 10.1016/j.omtn.2020.09.015 URL
[17]	Bai Q, Hunzeker ZE, Zhu Z, et al. Cranberry extract is a potent radiosensitizer for glioblastoma[J]. Anticancer Res, 2021, 41(7):3337-3341. doi: 10.21873/anticanres.15121 URL
[18]	Alharbi M, Mobark NA, Balbaid A, et al. Regression of ETV6-NTRK3 infantile glioblastoma after first-line treatment with larotrectinib[J]. JCO Precis Oncol, 2020, 4(4):796-800.
[19]	Xia H, Qi Y, Ng SS, et al. MicroRNA-146b inhibits glioma cell migration and invasion by targeting MMPs[J]. Brain Res, 2009, 1269(10):158-165. doi: 10.1016/j.brainres.2009.02.037 URL
[20]	Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMA, 2017, 317(13):1338-1348. doi: 10.1001/jama.2017.2719 URL
[21]	Jahanbani I, Abdallah A, Ali RH, et al. Discriminatory miRNAs for the management of papillary thyroid carcinoma and noninvasive follicular thyroid neoplasms with papillary-like nuclear features[J]. Thyroid, 2018, 28(3):319-327. doi: 10.1089/thy.2017.0127 pmid: 29378472
[22]	Abdallah A, Jahanbani I, Mehdawi H, et al. The stress-activated protein kinase pathway and the expression of stanniocalcin-1 are regulated by miR-146b-5p in papillary thyroid carcinogenesis[J]. Cancer Biol Ther, 2020, 21(5):1-12. doi: 10.1080/15384047.2019.1665395 URL
[23]	Lima CR, Geraldo MV, Fuziwara CS, et al. MiRNA-146b-5p upregulates migration and invasion of different papillary thyroid carcinoma cells[J]. BMC Cancer, 2016, 16(1):108. doi: 10.1186/s12885-016-2146-z URL
[24]	Li LC, Bin LV, Chen B, et al. Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression[J]. Biochem Biophys Res Commun, 2015, 462(4):314-321. doi: 10.1016/j.bbrc.2015.04.134 URL
[25]	Santisteban P, Eizaguirre G, Lamas L, et al. The miR-146b-3p/PAX8/NIS regulatory circuit modulates the differentiation phenotype and function of thyroid cells during carcinogenesis[J]. Cancer Res, 2015, 75(19):4119-4130. doi: 10.1158/0008-5472.CAN-14-3547 URL
[26]	Reck M, Rodríguez D, Robinson AG, et al. Pembrolizu-mab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833. doi: 10.1056/NEJMoa1606774 URL
[27]	Borghaei H, Pazares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. New Engl J Med, 2015, 373(17):1627-1639. doi: 10.1056/NEJMoa1507643 URL
[28]	Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses[J]. Cell, 2017, 169(4):750-765. doi: 10.1016/j.cell.2017.04.014 URL
[29]	Han Q, Cheng P, Yang H, et al. MiR-146b reverses epithelial-mesenchymal transition via targeting PTP1B in cisplatin-resistance human lung adenocarcinoma cells[J]. J Cell Biochem, 2019, 24(7):1-12. doi: 10.1002/(ISSN)1097-4644 URL
[30]	Li Y, Zhang HB, Dong YL, et al. MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer[J]. J Cancer, 2017, 8(9):1704-1712. doi: 10.7150/jca.16961 URL
[31]	Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136:1921-1930. doi: 10.1002/ijc.29227 URL
[32]	Li C, Miao R, Liu S, et al. Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis[J]. Oncotarget, 2017, 8(17):28683-28695. doi: 10.18632/oncotarget.v8i17 URL
[33]	Ding W, Yang H, Gong S, et al. Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis[J]. Oncol Lett, 2017, 13(5):3409-3414. doi: 10.3892/ol.2017.5913 URL
[34]	Fan KY, Dholakia AS, Wild AT, et al. Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer[J]. J Natl Compr Canc Netw, 2019, 12(1):50-57. doi: 10.6004/jnccn.2014.0006 URL
[35]	Kudo M, Kobayashi T, Gotohda N, et al. Clinical utility of histological and radiological evaluations of tumor necrosis for predicting prognosis in pancreatic cancer[J]. Pancreas, 2020, 49(5):634-641. doi: 10.1097/MPA.0000000000001539 URL
[36]	Zhang B, Pan X, Cobb GP, et al. MicroRNAs as onco-genes and tumor suppressors[J]. Dev Biol, 2007, 302(1):1-12. doi: 10.1016/j.ydbio.2006.08.028 URL
[37]	Lin F, Wang X, Jie Z, et al. Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16[J]. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(4):509. doi: 10.1007/s11596-011-0481-5 URL
[38]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics,2012[J]. CA Cancer J Clin, 2013, 65(2):87-108. doi: 10.3322/caac.21262 URL
[39]	Byeon JS, Yang SK, Kim TI, et al. Colorectal neoplasm in asymptomatic Asians: a prospective multinational multicenter colonoscopy survey[J]. Gastrointest Endosc, 2007(65): 1015-1022.
[40]	Zhu Y, Wu G, Yan W, et al. MiR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer[J]. Am J Cancer Res, 2017, 7(5):1136.

miR-146b在恶性肿瘤中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈思晗, 熊虎, 税典雅, 高小瞻, 刘泽伟. 超微血管成像技术诊断乳腺肿瘤的meta分析[J]. 临床荟萃, 2024, 39(2): 108-114.
[2]	赵旭辉, 黄小敏, 达德转, 许焱, 崔晓东, 李红玲. 基于生物信息学筛选影响胃癌患者预后的糖酵解相关基因[J]. 临床荟萃, 2024, 39(1): 20-29.
[3]	黄赛虎, 龙中洁, 董兴强, 孟祥营, 吴水燕, 柏振江. 血液肿瘤患儿合并脓毒血症的病原学特点及临床特征[J]. 临床荟萃, 2024, 39(1): 38-42.
[4]	吕畅, 周利明. TNF-α-308基因多态性与胃癌易感相关性的meta分析[J]. 临床荟萃, 2023, 38(9): 779-787.
[5]	武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.
[6]	侯有玲, 李奕, 关红玉, 罗红霞. 目标导向液体治疗在脑肿瘤切除术中应用效果的meta分析[J]. 临床荟萃, 2023, 38(8): 686-693.
[7]	李亚, 杜涛明, 邱世香, 陈超, 钟立明. 伴有抑郁症状肝癌患者脑功能连接研究[J]. 临床荟萃, 2023, 38(6): 532-536.
[8]	王英南, 赵琦, 白海威, 武丹娜, 魏金梅, 李省江, 李锐凌, 张瑞星. 胃癌合并脑梗死的临床特点及危险因素分析[J]. 临床荟萃, 2023, 38(5): 417-422.
[9]	周腾腾, 李来有, 刘志敏, 左静. 隧道式和传统PICC穿刺法对导管相关血流感染影响的研究进展[J]. 临床荟萃, 2023, 38(5): 469-472.
[10]	陆知非, 王高卿, 高过. 肝门部胆管癌的非手术治疗进展[J]. 临床荟萃, 2023, 38(5): 473-476.
[11]	黎恒楠, 黄艳, 赵亚娟, 胡桂才. 血清CTRP5与持续非卧床腹膜透析患者左室舒张功能异常的相关性及其诊断价值[J]. 临床荟萃, 2023, 38(4): 324-329.
[12]	罗杰, 吴强, 李忠, 郑硕. 罕见肾上腺神经纤维瘤1例并文献复习[J]. 临床荟萃, 2023, 38(4): 359-363.
[13]	彭灵智, 祝成楼, 刘天祥. 超级增强子:肿瘤治疗的新靶点[J]. 临床荟萃, 2023, 38(3): 273-278.
[14]	祝成楼, 吴琼, 达明绪. 西格列汀治疗2型糖尿病的胰腺癌风险评估:来自随机对照试验的荟萃分析结果[J]. 临床荟萃, 2023, 38(12): 1061-1066.
[15]	王军宏, 高振华, 章荣龙, 姬浩民, 赵信科, 达明绪. 1980-2021年胃癌诊断文献相关质量分析——基于Web of Science 数据库的文献计量学分析[J]. 临床荟萃, 2023, 38(12): 1117-1124.